Pharvaris (PHVS) to Release Earnings on Tuesday

Key Points

• Pharvaris will release its Q4 2025 results before the market opens on Tuesday, April 14, and analysts expect an earnings loss of ($0.69) per share; a conference call is listed for Thursday, April 9 at 12:30 PM ET.
• Shares opened at $28.37 with a market capitalization of $1.54 billion, a 12‑month low/high of $11.51/$29.85, and a negative PE of -8.42.
• Wall Street consensus is a Moderate Buy (10 Buy, 2 Hold, 1 Sell) with an average price target of $41.60, though individual firm views range from HC Wainwright's $60 Buy to Weiss Ratings' Sell.

Pharvaris (NASDAQ:PHVS - Get Free Report) is expected to release its Q4 2025 results before the market opens on Tuesday, April 14th. Analysts expect Pharvaris to post earnings of ($0.69) per share for the quarter. Interested persons can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, April 9, 2026 at 12:30 PM ET.

Pharvaris Trading Down 0.7%

NASDAQ PHVS opened at $28.37 on Tuesday. The business's 50-day moving average price is $27.07 and its two-hundred day moving average price is $25.47. Pharvaris has a 12 month low of $11.51 and a 12 month high of $29.85. The firm has a market capitalization of $1.54 billion, a PE ratio of -8.42 and a beta of -2.58.

Institutional Investors Weigh In On Pharvaris

Several institutional investors and hedge funds have recently made changes to their positions in PHVS. Geode Capital Management LLC boosted its position in shares of Pharvaris by 41.1% during the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company's stock valued at $952,000 after purchasing an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter. Amundi boosted its position in shares of Pharvaris by 2,741,600.0% during the 2nd quarter. Amundi now owns 27,417 shares of the company's stock valued at $489,000 after purchasing an additional 27,416 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Pharvaris by 19.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company's stock valued at $860,000 after purchasing an additional 7,879 shares in the last quarter.

Wall Street Analysts Forecast Growth

PHVS has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. Royal Bank Of Canada decreased their price target on Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a research note on Monday. Wall Street Zen cut Pharvaris from a "hold" rating to a "sell" rating in a research note on Sunday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Pharvaris in a research note on Thursday, January 22nd. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $41.60.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.